AI-enabled medical devices with limited pre-market validation are more likely to be recalled after FDA clearance.
Key Details
- 1AI-enabled device recalls are more common among those lacking prospective human validation prior to FDA 510(k) clearance.
- 2Most AI medical devices are cleared without requiring prospective clinical testing.
- 3Study reviewed all U.S. recalls of AI-enabled devices between Nov. 15–30, 2024.
- 4Validation method (none, retrospective, or prospective) was a notable factor influencing recall likelihood.
- 5Recalls were categorized into errors such as diagnostic, measurement, and functional issues.
Why It Matters
These findings highlight the inadequacy of current FDA pathways to ensure AI device reliability and safety in clinical environments. For radiology professionals and developers, the results underscore the critical importance of robust validation before market approval.
Source
Health Imaging
Related News
•Radiology Business
Framework Assesses Real-World Financial Impact of Radiology AI Adoption
A new analysis presents a financial calculator for objectively assessing the return on investment (ROI) of implementing radiology AI solutions.
•Radiology Business
AI Technique Unveils Previously Hidden MS Gray Matter Lesions on MRI
Researchers developed an AI-enhanced method to detect previously invisible gray matter lesions in multiple sclerosis using MRI.
•Radiology Business
Majority of Patients Want Disclosure When AI Used in Imaging
A new survey finds that nearly all patients want to be informed when AI is utilized in medical imaging interpretation.